ArticleActa veterinaria Scandinavica2025
Medetomidine-vatinoxan-methadone and acepromazine-methadone: comparison of sedative and cardiovascular properties as a preanaesthetic medication in healthy dogs.
Article in Acta veterinaria Scandinavica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedetomidine-vatinoxan is a relatively new medicinal product indicated for sedation of healthy dogs. Vatinoxan alleviates medetomidine-induced bradycardia and peripheral vasoconstriction in dogs, but when used as a preanaesthetic medication, it has been shown to cause more hypotension during general anaesthesia compared to medetomidine alone. Our aim was to compare medetomidine-vatinoxan to acepromazine when used as a preanaesthetic medication in a randomised, blinded, clinical study. Healthy client-owned dogs (n = 25) scheduled for elective ovariectomy were randomly assigned to receive 0.2 mg/kg intramuscular methadone combined with either 0.01 mg/kg medetomidine and 0.2 mg/kg vatinoxan (group MV, n = 13) or 0.02 mg/kg acepromazine (group A, n = 12). A sedation scale (SS, range 0-12) and visual analogue scale (VAS, range 0-100 mm) were applied to assess sedation every 5 min until one of the following endpoints was reached: the SS was ≥ 6 or30 min from treatment had passed. After this, general anaesthesia was induced with propofol and maintained with sevoflurane vaporised in oxygen. The need for cardiovascular interventions according to current guidelines was recorded. Statistical comparisons were performed with Student's t test, the Mann‒Whitney U test and Fisher's exact test. P-values < 0.05 were considered statistically significant.
resultsThe median (range) time to achieve an SS ≥ 6 was 5 (5-10) minutes in the MV group and 20 (10-25) minutes in the A group (P-value < 0.001). The number of dogs needing interventions for hypotension, bradycardia and/or bradyarrhytmias (7 in group MV, 8 in group A) did not significantly differ between the groups.
conclusionsWhen used as a preanaesthetic medication in combination with methadone, medetomidine-vatinoxan causes faster onset of sedation, without statistically significant differences in cardiovascular interventions, compared to acepromazine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.